Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496613 · ClinicalTrials.gov registry record
Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 200
- Enrollment target
NCT00496613: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00496613 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496613 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how chemotherapy affects an individual's thinking abilities (cognition). Some research has shown that chemotherapy can cause changes in cognition in breast cancer survivors. However, it is not clear why this change occurs. In this study, the investigators will look to see if damage to DNA is related to these changes in cognition. Specifically, the investigators want to see 1) if women who have been treated with chemotherapy have more DNA damage than healthy women; and 2) if DNA damage is related to cognitive problems in breast cancer survivors and healthy women.
Interventions
- BEHAVIORAL Mini-Mental State Exam and Blood draw
- BEHAVIORAL Mini-Mental State Exam and Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2007-06 |
| Est. Completion | 2022-04-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496613
The ClinicalTrials.gov registry entry for NCT00496613 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mini-Mental State Exam and Blood draw is the first listed.
NCT00496613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496613 about?
NCT00496613 is a clinical study titled "Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors". The purpose of this study is to learn more about how chemotherapy affects an individual's thinking abilities (cognition). Some research has shown that chemotherapy can cause changes in cognition in breast cancer survivors. However, it is not clear why this change occurs. In this study, the investiga...
What is the current status of trial NCT00496613?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2007-06. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT00496613?
The interventions under investigation include: Mini-Mental State Exam and Blood draw (BEHAVIORAL), Mini-Mental State Exam and Blood Draw (BEHAVIORAL).
Who is sponsoring clinical trial NCT00496613?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.